Case 22

Patient #22, a 69 year-old woman with a past medical history of chronic kidney disease, hypothyroidism, severe congestive heart failure with reduced ejection fraction, prosthetic knee joint infection, and a history of bacteremia. In November 2016, she had a left ventricular assist device (LVAD) placed and a right knee arthroplasty. Over a 4 year period

Case 13

Patient #13, a 10-year-old female diagnosed with cystic fibrosis, who was admitted to the hospital for CF exacerbation with an Achromobacter xylosidans infection resistant to all available antibiotics. The patient was initially treated with the experimental antibiotic cefiderocol and 17 days later she began her phage therapy. During the first 5 days of phage therapy,

Case 9

Patient #9, an 18-year-old female who underwent a kidney transplant in March 2018 which prompted multiple episodes of bacteremia and urosepsis caused by an extended spectrum beta-lactamase (ESBL) producing strain of Escherichia coli. Phage therapy consisting of two different phage products with titers ranging from 1.0 x 10^9 to 1.0 x 10^10 PFU/mL was first